CONFERENCE DAY ONE
SEPTEMBER 9, 2024
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and hyper-relevant partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format, to find you your next partner and route to more capital.
8.00-9.00: Activity in ADCs, Appetite for Radioligands & Alignment for Business from the Pharma Icebreaker
9.00-9.30: Investor Interests to Actively Finance Innovation with the Venture Panel
10.15-12.15: Face-to-face protected networking time during the Search & Evaluation Roundtables to qualify, hear feedback, and generate interest for the rest of the conference.
7:45 am Chair’s Opening Remarks
STRATEGIC PRIORITIES & DEAL TRENDS FOR FUTURE COLLABORATIONS & INVESTMENT IN ADC & RADIOLIGANDS
8:00 am Pharma Icebreaker: Activity in ADCs, Appetite for Radioligands & Alignment for Business
Synopsis
- Discussing recent deal-making and current search and evaluation interests for context in the conference to follow
- Sharing insights into decision-making, due diligence, and necessary data packages to more confidently bring information to networking conversations
- Collectively hypothesizing future radioligand and ADC trends to present the buyer’s perspective on the potential of innovation in earlier development
9:00 am The Venture Panel: Investor Interests to Actively Finance Innovations, Provide Capital & Capabilities, & Participate in Fundraising for Early Science
Synopsis
- Sharing relevant investments to date across ADC and radiopharmaceutical portfolios to evaluate specific venture interests and expertise
- Discussing desirable science to add to portfolios and how companies can position themselves for investment in this competitive market
- Drawing upon examples of significant series funding and investment to suggest new trends in exciting science
9:30 am Morning Break & Networking
10:15 am Search & Evaluation Roundtables for Pharma Partnerships
Synopsis
- Immerse yourself in the most valuable networking of the conference, and qualify yourself as a valuable prospect through face-to-face meetings with the pharma faculty.
- Rotate through pharma tables to understand how you align with search and evaluation interests, hear in-person feedback, and introduce your ADC innovations to multiple stakeholders.
- Select your tables ahead of time, and attend four 30-minute meetings across 2 hours of protected networking time.
12:15 pm Lunch Break & Networking
PART TWO: SHOWCASE YOUR SCIENCE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase
your pipeline, platform, and technologies to a room of aligned and qualified decision-makers.
BRINGING CLARITY TO THE DEAL FRENZY: CLINICAL PROGRESS & CAPITAL INVESTED IN THE LAST 12 MONTHS
1:15 pm Clinical Data, Deals & Company Analysis Across the ADCs & Radiopharmaceuticals
Synopsis
- Summarizing clinical and partnership developments to track the increasingly global ADC landscape
- Understanding venture investment to evaluate the potential of early discovery and preclinical science
- Reviewing the direction of global partnerships, specifically why there are so many deals being done with Asia
RADIOPHARMACEUTICALS & NOVEL ANTIBODY FORMATS: MARRYING NOVEL ADC FORMATS WITH RADIOISOTYPES TO IMPROVE TUMOR SELECTIVITY & CREATE EXCITING THERAPEUTIC POTENTIAL
1:45 pm A Version of ADCs: Antibody Formats Amenable to Improving PK/PD of Radiopharmaceuticals
Synopsis
- Discussing differences in the mechanisms of action for an ADC versus radiopharmaceutical
- Exploring different antibody fragments to target and deliver radioactivity to the tumor and generate a good half-life locally
- Insights into novel click cleavable ADCs for delivery of radiotherapeutics
2:10 pm AvDCs (Avibody Drug Conjugates): A Targeted Approach to Efficacy, Improved Tolerability & Favorable PK for Targeted Radio-Therapy, Novel ADC Formats, & Enhanced Tumor Selectivity
Synopsis
- Avibodies are engineered, bivalent mAb fragments, precisely loaded with radiotoxic or cytotoxic payloads
- Sharing pre-clinical data demonstrating traditional ADC, novel pre-targeting, and targeted radio therapy formats
- Biparatopic or bispecific designs against TSEs (Tumor Specific Epitopes) can further enhance solid tumor selectivity
2:30 pm The Radiopharmaceutical Fork in the Road: Radioantibodies versus Radioligands
Synopsis
- Does the success of Lutathera and Pluvicto foretell a wave of effective Radioligands
- Paradoxical advantages/disadvantages of ligands and antibodies
- Blending Radioantibodies and Radioligands: the ideal Radiopharmaceutical approach
2:50 pm Afternoon Break & Networking
CONJUGATION & CLICK RELEASE CHEMISTRY: STABILITY, SOLUBILITY & TUMOR SPECIFICITY
3:20 pm Why Are ADCs a Strategic Pillar at Debiopharma?
Synopsis
- Debiopharm’s perspectives on why we believe ADCs are hot
- Our approach to add value for out-licensing partners
3:40 pm Click-Cleavable ADCs
Synopsis
- Expanding the therapeutic window and application scope of ADCs through in vivo click release chemistry, to increase efficacy and decrease toxicity
- Updates on TGW101, targeting TAG72, inaccessible with current ADC technologies
- Insights to radiotherapeutics programs to date
4:00 pm CytomX: PROBODY® Conditional Activation Technology Designed to Expand ADC Target Landscape
Synopsis
- Sharing industry-leading PROBODY® masking technology which leverages elevated protease activity in the tumor microenvironment and is designed to increase the therapeutic index by reducing on-target off-tumor toxicities while potentially maintaining potent anti-tumor efficacy
- Discussing PROBODY® platform with proof of mechanism: stability in circulation, intratumoral activation and single agent activity across multiple indications
- Outlining how PROBODY® technology is designed to unlock EpCAM as a systemic ADC target (CX-2051, PROBODY® EpCAM-Topo1 ADC currently in Ph1) and may be applied to other ADC targets with low or negative therapeutic index
4:20 pm Tubulis – Reimagining ADCs From Concept to Clinics
Synopsis
- Expanding the therapeutic potential of protein-drug conjugate through increased design flexibility, leveraging the right platform to create ADCs with superior biophysical properties
- Updates on Tubulis’ proprietary programs
- Seeking new conjugates to fill Tubulis’ pipeline and collaborations for the new era of ADCs
4:40 pm Developing Next-generation Targeted Therapies using Click Chemistry
Synopsis
- Introducing Shasqi's Click Activated Protodrugs Against Cancer (CAPAC), how it overcomes the major limitation of ADC and RLT approaches by separating tumor antigen binders from payloads, reuniting them at the tumor via click chemistry
- Discussing CAPAC design heuristics and methods that inform therapeutic design
- Updates on Shasqi’s proprietary programs
5:00 pm Chair’s Closing Remarks
Drinks Reception & ADC Shark Tank:
5.20: “People work with people”. Catch up with the field in Boston, and candidly network during the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Drinks Reception, to initiate and reinforce existing business relationships built before or during the conference so far.
Get in touch about quick-fire 7-minute pitch opportunities to a panel of industry leaders, to hear constructive feedback on future fundraising or development strategies directly.